Loading...
ETON logo

Eton Pharmaceuticals, Inc.NasdaqGM:ETON Stock Report

Market Cap US$483.0m
Share Price
US$18.01
My Fair Value
US$30
40.0% undervalued intrinsic discount
1Y108.9%
7D-2.4%
Portfolio Value
​
View

Eton Pharmaceuticals, Inc.

NasdaqGM:ETON Stock Report

Market Cap: US$483.0m

Eton Pharmaceuticals (ETON) Stock Overview

A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. More details

ETON fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 82.2% below our estimate of its fair value

Earnings are forecast to grow 50.75% per year

Earnings have grown 43.5% per year over the past 5 years

Analysts in good agreement that stock price will rise by 66.6%

Risk Analysis

Significant insider selling over the past 3 months


ETON Community Fair Values

Create Narrative

See what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.

ETON logo
Eton Pharmaceuticals

Aging Population And Improved Diagnosis Will Unlock Orphan Drug Markets

Key Takeaways Expansion of patient access and label indications could rapidly accelerate growth and significantly boost both revenue and operating margins beyond current expectations. Eton's proven execution in specialty acquisitions and favorable industry trends uniquely position it for sustained outsized demand and above-trend earnings growth.
View narrative
US$35
FV
48.5% undervalued intrinsic discount
51.15%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
ETON logo
Eton Pharmaceuticals

Orphan Drug Reliance Will Confront Regulatory Hurdles Yet Regain Traction

Key Takeaways Heightened regulatory scrutiny and policy reforms could limit revenue growth and put pressure on Eton's drug pricing and profitability. Dependence on a small product portfolio and external licensing may expose Eton to competition risks and constrain future innovation and earnings stability.
View narrative
US$26
FV
30.7% undervalued intrinsic discount
36.62%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
ETON logo
Eton Pharmaceuticals

Advances In Diagnosis And Orphan Drugs Will Open New Horizons

Key Takeaways Expansion in ultra-rare disease therapies, new product launches, and regulatory incentives strengthen growth prospects and improve margins. Investments in patient support, education, and targeted distribution drive higher adoption, recurring revenues, and faster scaling of profitability.
View narrative
US$30
FV
40.0% undervalued intrinsic discount
42.43%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
View Stock Community

Eton Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Eton Pharmaceuticals
Historical stock prices
Current Share PriceUS$18.01
52 Week HighUS$23.00
52 Week LowUS$8.24
Beta1.16
1 Month Change-9.63%
3 Month Change25.16%
1 Year Change108.93%
3 Year Change617.53%
5 Year Change159.14%
Change since IPO188.16%

Recent News & Updates

Eton Pharmaceuticals Has Focused Growth But Valuation Limits Upside: Why I Choose To Hold

Oct 25

Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Responsibly

Sep 24
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Responsibly

Recent updates

Eton Pharmaceuticals Has Focused Growth But Valuation Limits Upside: Why I Choose To Hold

Oct 25

Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Responsibly

Sep 24
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Responsibly

Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 25% Cheaper Price Remains In Tune With Revenues

Jun 17
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 25% Cheaper Price Remains In Tune With Revenues
User avatar

Increlex And Galzin Acquisitions Will Broaden Treatment Options

Strategic acquisitions and product launches are expected to drive significant revenue growth and expand market reach in pediatrics and rare diseases.

Results: Eton Pharmaceuticals, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts

May 16
Results: Eton Pharmaceuticals, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts

Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33%

May 02
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33%

Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 45% Jump Shows Its Popularity With Investors

Feb 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 45% Jump Shows Its Popularity With Investors

Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%

Nov 14
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%

Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?

Oct 07
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?

After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Sep 10
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Dec 22
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous

Sep 13

Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story

Aug 14

Eton Pharma jumps 20% on FDA approval of seizure therapy

Jul 18

Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Apr 15
Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Oct 14
Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Another Look At Eton Pharmaceuticals

Sep 03

What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Aug 18
What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Shareholder Returns

ETONUS PharmaceuticalsUS Market
7D-2.4%1.8%0.5%
1Y108.9%2.1%20.1%

Return vs Industry: ETON exceeded the US Pharmaceuticals industry which returned 2.1% over the past year.

Return vs Market: ETON exceeded the US Market which returned 20% over the past year.

Price Volatility

Is ETON's price volatile compared to industry and market?
ETON volatility
ETON Average Weekly Movement6.9%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.4%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market3.0%

Stable Share Price: ETON has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ETON's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201731Sean Brynjelsenwww.etonpharma.com

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis.

Eton Pharmaceuticals, Inc. Fundamentals Summary

How do Eton Pharmaceuticals's earnings and revenue compare to its market cap?
ETON fundamental statistics
Market capUS$482.98m
Earnings (TTM)-US$4.13m
Revenue (TTM)US$58.18m
8.3x
P/S Ratio
-117.0x
P/E Ratio

Is ETON overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ETON income statement (TTM)
RevenueUS$58.18m
Cost of RevenueUS$21.27m
Gross ProfitUS$36.91m
Other ExpensesUS$41.04m
Earnings-US$4.13m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Nov 06, 2025

Earnings per share (EPS)-0.15
Gross Margin63.44%
Net Profit Margin-7.10%
Debt/Equity Ratio125.9%

How did ETON perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/02 00:48
End of Day Share Price 2025/10/31 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eton Pharmaceuticals, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madison Wynne El-SaadiB. Riley Securities, Inc.
Chase KnickerbockerCraig-Hallum Capital Group LLC
Swayampakula RamakanthH.C. Wainwright & Co.